Erythropoiesis-stimulating agents in sickle cell anaemia.
作者信息
Han Jin, Zhou Jifang, Kondragunta Vinod, Zhang Xu, Molokie Robert E, Gowhari Michel, Hassan Johara, Jain Shivi, Calip Gregory S, Gordeuk Victor R, Saraf Santosh L
机构信息
Division of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, IL, USA.
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
出版信息
Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27.
Abstract
摘要
相似文献
1
Erythropoiesis-stimulating agents in sickle cell anaemia.镰状细胞贫血中的促红细胞生成素
Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27.
2
Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.促红细胞生成素刺激剂治疗化疗所致贫血患者的剂量效率：一项系统评价
Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18.
3
Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.接受腹膜透析患者中，达贝泊汀α与聚乙二醇化促红细胞生成素β治疗的疼痛及疗效比较。
J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.
4
Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.评估罗沙司他和达贝泊汀对镰状细胞病患者血红蛋白水平的影响。
Expert Rev Hematol. 2024 Jun;17(6):255-260. doi: 10.1080/17474086.2024.2352497. Epub 2024 May 16.
5
Darbepoetin Administration in Term and Preterm Neonates.促红细胞生成素在足月儿和早产儿中的应用。
Clin Perinatol. 2015 Sep;42(3):557-66. doi: 10.1016/j.clp.2015.04.016. Epub 2015 May 23.
6
Darbepoetin alfa for anemia with myelodysplastic syndrome.聚乙二醇化促红细胞生成素α用于治疗骨髓增生异常综合征所致贫血
Expert Rev Hematol. 2015 Apr;8(2):139-46. doi: 10.1586/17474086.2015.1000854. Epub 2015 Jan 12.
7
Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin.用达贝泊汀和促红细胞生成素治疗的早产儿的学前评估
Pediatrics. 2016 Mar;137(3):e20153859. doi: 10.1542/peds.2015-3859. Epub 2016 Feb 15.
8
Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia.
Pharmacotherapy. 2003 Dec;23(12 Pt 2):110S-118S. doi: 10.1592/phco.23.16.110s.31970.
9
Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.达比加群酯给药方案的改变会影响接受血液透析的慢性肾病患者对促红细胞生成素的抵抗。
Ren Fail. 2008;30(8):778-83. doi: 10.1080/08860220802248977.
10
An overview of the pharmacokinetic disposition of darbepoetin alfa.
Pharmacotherapy. 2002 Sep;22(9 Pt 2):133S-140S. doi: 10.1592/phco.22.14.133s.33396.
引用本文的文献
1
Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model.钠-葡萄糖共转运蛋白 2 抑制剂可改善镰状细胞病小鼠和人类的贫血，并减少小鼠卒中模型中的梗死面积。
J Cell Mol Med. 2024 Sep;28(17):e70091. doi: 10.1111/jcmm.70091.
2
Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease.溶血驱动的 IFNα 产生通过负向调节镰状细胞病中的 EPO 信号转导来损害红细胞生成。
Blood. 2024 Mar 14;143(11):1018-1031. doi: 10.1182/blood.2023021658.
3
Sickle Cell Disease and CKD: An Update.镰状细胞病与慢性肾脏病：最新进展。
Am J Nephrol. 2024;55(1):56-71. doi: 10.1159/000534865. Epub 2023 Oct 27.
4
Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.重新审视镰状细胞病中的贫血症，并找到治疗方法的平衡点。
Blood. 2022 May 19;139(20):3030-3039. doi: 10.1182/blood.2021013873.
5
The nephropathy of sickle cell trait and sickle cell disease.镰状细胞性状和镰状细胞病的肾病
Nat Rev Nephrol. 2022 Jun;18(6):361-377. doi: 10.1038/s41581-022-00540-9. Epub 2022 Feb 21.
6
Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.利用行政数据识别镰状细胞病：美国卫生服务研究中方法的批判性回顾。
Pediatr Blood Cancer. 2020 Dec;67(12):e28703. doi: 10.1002/pbc.28703. Epub 2020 Sep 17.
7
The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.红细胞祖细胞中的促红细胞生成素-成纤维细胞生长因子23信号通路：开启一个新的研究领域。
Front Physiol. 2019 Mar 26;10:304. doi: 10.3389/fphys.2019.00304. eCollection 2019.
本文引用的文献
1
Identification and Validation of a Sickle Cell Disease Cohort Within Electronic Health Records.电子健康记录中镰状细胞病队列的识别与验证
Acad Pediatr. 2017 Apr;17(3):283-287. doi: 10.1016/j.acap.2016.12.005. Epub 2016 Dec 13.
2
3
F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study.
Blood. 1993 Jan 1;81(1):9-14.
4
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.关于羟基脲/促红细胞生成素联合疗法治疗镰状细胞病的应用
Acta Haematol. 1995;94(3):128-34. doi: 10.1159/000203994.
5
Erythropoietin and renal function in sickle-cell disease.镰状细胞病中的促红细胞生成素与肾功能
Br Med J (Clin Res Ed). 1982 Dec 11;285(6356):1686-8. doi: 10.1136/bmj.285.6356.1686.
6
7
Erythropoietin in anemia of renal failure in sickle cell disease.促红细胞生成素在镰状细胞病肾衰竭贫血中的应用
N Engl J Med. 1991 Oct 17;325(16):1175-6. doi: 10.1056/NEJM199110173251614.
8
Erythropoietin for anemia of renal failure in sickle cell disease.促红细胞生成素用于镰状细胞病肾衰竭贫血
N Engl J Med. 1991 May 9;324(19):1369-70. doi: 10.1056/NEJM199105093241916.
9
Treatment of sickle cell anemia with hydroxyurea and erythropoietin.用羟基脲和促红细胞生成素治疗镰状细胞贫血。
N Engl J Med. 1990 Aug 9;323(6):366-72. doi: 10.1056/NEJM199008093230602.
10
Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.重组人促红细胞生成素对纯合子镰状细胞贫血和肾衰竭患者红细胞生成的影响。
Nephrol Dial Transplant. 1992;7(8):817-21.
Zotero 插件